Mouse models of PDAC treated with lorlatinib (an FDA-approved inhibitor of anaplastic lymphoma kinase, or ALK) demonstrated a reduction in tumor progression mediated by inhibition of neutrophil development and mobilization [34]. The gene discussed is ALK; the disease is neoplasm.